JP2020528082A5 - - Google Patents

Download PDF

Info

Publication number
JP2020528082A5
JP2020528082A5 JP2020524719A JP2020524719A JP2020528082A5 JP 2020528082 A5 JP2020528082 A5 JP 2020528082A5 JP 2020524719 A JP2020524719 A JP 2020524719A JP 2020524719 A JP2020524719 A JP 2020524719A JP 2020528082 A5 JP2020528082 A5 JP 2020528082A5
Authority
JP
Japan
Prior art keywords
seq
cpp
sequence listing
therapeutic agent
rpe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020524719A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020528082A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/042410 external-priority patent/WO2019018350A1/en
Publication of JP2020528082A publication Critical patent/JP2020528082A/ja
Publication of JP2020528082A5 publication Critical patent/JP2020528082A5/ja
Pending legal-status Critical Current

Links

JP2020524719A 2017-07-17 2018-07-17 加齢黄斑変性と他の眼疾患の治療用の細胞透過性ペプチドを使用する治療薬の局所送達 Pending JP2020528082A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762533231P 2017-07-17 2017-07-17
US62/533,231 2017-07-17
PCT/US2018/042410 WO2019018350A1 (en) 2017-07-17 2018-07-17 TOPICAL ADMINISTRATION OF THERAPEUTIC AGENTS COMPRISING CELL PENETRATION PEPTIDES, FOR USE IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER OCULAR DISEASES

Publications (2)

Publication Number Publication Date
JP2020528082A JP2020528082A (ja) 2020-09-17
JP2020528082A5 true JP2020528082A5 (2) 2021-10-21

Family

ID=63104068

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020524719A Pending JP2020528082A (ja) 2017-07-17 2018-07-17 加齢黄斑変性と他の眼疾患の治療用の細胞透過性ペプチドを使用する治療薬の局所送達

Country Status (8)

Country Link
US (2) US10905770B2 (2)
EP (1) EP3654941A1 (2)
JP (1) JP2020528082A (2)
CN (1) CN112996486A (2)
AU (1) AU2018302022A1 (2)
CA (1) CA3070241A1 (2)
IL (1) IL272105A (2)
WO (1) WO2019018350A1 (2)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200134287A (ko) * 2018-04-02 2020-12-01 젠켐 테크놀로지 컴퍼니 리미티드 (베이징) 타겟성을 구비하는 세포막 투과 펩타이드-다중팔 폴리에틸렌글리콜-약물 켤레체 및 그 응용
WO2019195136A1 (en) 2018-04-03 2019-10-10 Ngm Biopharmaceuticals, Inc. C3-binding agents and methods of use thereof
TW202009013A (zh) * 2018-08-14 2020-03-01 優你康光學股份有限公司 具有功能性成分的隱形眼鏡及其產品
GB201900728D0 (en) * 2019-01-18 2019-03-06 Univ Birmingham Drug delivery system
US12115212B2 (en) * 2019-01-18 2024-10-15 L & J Bio Co., Ltd. Methods of decreasing amyloid beta (Aβ) plaque deposition and hyperphosphorylated tau plaque deposition in Alzheimer's disease using a cystatin C fusion protein
EP3934675A2 (en) * 2019-03-08 2022-01-12 RA Pharmaceuticals, Inc. Zilucoplan as deep tissue penetrating c5 inhibitor
JP7668227B2 (ja) * 2019-04-08 2025-04-24 バイオクライスト ファーマシューティカルズ, インコーポレイテッド 血漿カリクレイン阻害剤および眼障害におけるその使用方法
WO2020252453A1 (en) * 2019-06-14 2020-12-17 The Brigham And Women's Hospital, Inc. Membrane attack complexes and uses thereof
WO2021087399A1 (en) * 2019-10-30 2021-05-06 Perfuse Therapeutics, Inc. Treatment of ocular diseases using endothelin receptor antagonists
PL3886858T3 (pl) * 2019-12-19 2022-08-29 Active Biotech Ab Związki do leczenia chorób oka związanych z nadmiernym unaczynieniem
CN115103842A (zh) 2020-02-06 2022-09-23 珀弗斯治疗股份有限公司 用于治疗眼部疾病的组合物
WO2021173999A1 (en) * 2020-02-28 2021-09-02 Northwestern University Method of enhancing aqueous humor outflow and reducing intraocular pressure
US20230173024A1 (en) * 2020-04-01 2023-06-08 The Trustees Of The University Of Pennsylvania Factor b inhibitors and uses thereof
US11754753B2 (en) * 2020-04-27 2023-09-12 Coopervision International Limited Antioxidant contact lens
FR3111913A1 (fr) * 2020-06-30 2021-12-31 Eyevensys Construction d’adn pour le traitement de pathologies oculaires
CN111671922B (zh) * 2020-07-23 2023-03-21 四川大学华西医院 两亲性梳形嵌段接枝共聚物基超声造影剂及其制备方法
CN114073774A (zh) * 2020-08-17 2022-02-22 奥朗生物医药有限公司 药物和野生型穿膜肽衍生物的组合物
CA3191819A1 (en) 2020-09-09 2022-03-17 Hazel Szeto Methods and compositions for delivery of biotin to mitochondria
KR102556731B1 (ko) * 2020-09-29 2023-07-21 주식회사 젠센 단백질 수송 도메인, 이를 포함하는 융합 화합물 및 이 융합 화합물을 포함하는 약학 조성물
MX2023003877A (es) * 2020-10-01 2023-04-18 Abionyx Pharma Sa Composiciones que comprenden complejos basados en proteina de union a lipidos para usarse en el tratamiento de enfermedades oculares.
MX2023004631A (es) * 2020-10-22 2023-07-20 Xequel Bio Inc Formulaciones peptidicas y usos oftalmicos de las mismas.
US20230399378A1 (en) * 2020-10-28 2023-12-14 The Florey Institute Of Neuroscience And Mental Health Peptide-based delivery of agents
CN114790225B (zh) * 2021-01-26 2024-09-10 清华大学 一种新型内体逃逸肽及其应用
US20220287968A1 (en) * 2021-03-09 2022-09-15 Florida State University Research Foundation, Inc. Lipid vesicle-mediated delivery to cells
CN113057142B (zh) * 2021-03-30 2022-12-09 四川大学华西医院 一种视网膜内和/或视网膜下纤维化动物模型的构建方法
WO2022216785A1 (en) * 2021-04-06 2022-10-13 University Of South Florida Peptide-small interfering rna-hyaluronic acid nanoparticles and methods of use thereof
AU2022264438A1 (en) * 2021-04-30 2023-11-23 Perfuse Therapeutics, Inc. Treatment of ocular diseases using endothelin receptor antagonists
CA3218251A1 (en) * 2021-04-30 2022-11-03 Perfuse Therapeutics, Inc. Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases
CN113332450B (zh) * 2021-05-11 2023-08-04 铜仁学院 一种眼部给药递释系统氧化锌纳米粒的制备方法及其使用方法和应用
CA3220626A1 (en) * 2021-05-28 2022-12-01 Aleksandar SKUBAN Use of complement factor d inhibitor for treatment of geographic atrophy secondary to age-related macular degeneration
CN113476587B (zh) * 2021-07-19 2022-07-12 河南大学 一种脑靶向的神经保护剂ss31-ha-rt及其制备方法和应用
CN113925966B (zh) * 2021-09-17 2022-10-04 西安电子科技大学 快速响应型细胞核靶向纳米诊疗探针的制备方法
CN114404429B (zh) * 2021-11-30 2023-06-30 重庆医科大学附属第二医院 一种纳米银修饰的单宁酸-铁网络的载药纳米复合物及其制备方法和逆转肿瘤耐药应用
KR102795182B1 (ko) * 2022-02-18 2025-04-15 (주)메디톡스 탈모 치료 또는 발모 촉진 활성을 갖는 폴리펩티드 및 그의 용도
US20230310380A1 (en) * 2022-04-05 2023-10-05 Alan Neil Glazier Methods, devices, and systems for treating lens protein aggregation diseases
AU2023250345A1 (en) 2022-04-06 2024-11-14 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
CN116444678B (zh) * 2022-10-18 2024-02-02 百葵锐(深圳)生物科技有限公司 一种具有真菌抗菌抑菌性能的新型多肽
WO2024102746A1 (en) * 2022-11-08 2024-05-16 Microcures, Inc. Methods and agents for treating neurotrophic keratitis
WO2024156871A1 (en) * 2023-01-27 2024-08-02 Glasspearl Oü Mixtures of lipid nanoparticles and cell penetrating peptides
WO2024160819A1 (en) 2023-01-30 2024-08-08 Consorcio Centro De Investigación Biomédica En Red Nanoparticles with antibodies for ocular treatment
WO2024178368A2 (en) * 2023-02-23 2024-08-29 Ohio State Innovation Foundation Therapeutic protein combinations
CN116270974B (zh) * 2023-03-09 2024-03-12 湖南大学 一种组合物、阿柏西普递送系统和制备方法
TWI877652B (zh) * 2023-06-14 2025-03-21 長庚大學 眼用藥物遞送載體及其應用
WO2025093129A1 (en) * 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor
WO2025093436A1 (en) * 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor
WO2025117721A1 (en) * 2023-11-27 2025-06-05 Massachusetts Institute Of Technology Reconstituted lipoprotein particles to rescue lipid defects in the alzheimer's brain
WO2025128821A1 (en) * 2023-12-12 2025-06-19 Juvena Therapeutics, Inc. Compositions and methods for adp-ribosylation factor molecular trafficking
WO2025147589A1 (en) * 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders
WO2025212745A1 (en) * 2024-04-04 2025-10-09 University Of Massachusetts Engineered adeno-associated virus (aav) capsid protein and uses thereof
CN118290598B (zh) * 2024-05-29 2024-09-27 深圳柏垠生物科技有限公司 重组纤连蛋白及其制备方法和应用
WO2026033482A1 (en) * 2024-08-08 2026-02-12 Universita' Degli Studi Di Torino Therapeutic contact lenses loaded with mucin-based nanoparticles
WO2025218146A1 (zh) * 2024-08-09 2025-10-23 山西医科大学 一种抑制眼部病理性血管新生的滴眼剂及其制备方法
CN118995345B (zh) * 2024-08-09 2025-09-26 山西医科大学 一种抑制角膜缺氧损伤和角膜新生血管的隐形眼镜护理液及其制备方法
WO2026034435A1 (ja) * 2024-08-09 2026-02-12 東亞合成株式会社 ペプチドフラグメント及びその利用
CN119746027A (zh) * 2025-01-10 2025-04-04 山东济肽生物科技有限公司 多肽组合物的应用及治疗衰老相关皮肤病的组合物
CN119792574B (zh) * 2025-01-10 2025-12-19 宁夏医科大学 一种仿生plga复合纳米材料及其制备方法与应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19548114C2 (de) 1995-12-21 2000-04-27 Deutsches Krebsforsch Konjugat, umfassend einen Wirkstoff, ein Polypeptid und einen Polyether
IL132941A0 (en) 1997-05-21 2001-03-19 Univ Leland Stanford Junior Composition and method for enhancing transport across biological membranes
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
ATE283013T1 (de) 1999-10-21 2004-12-15 Alcon Inc Medikamentenzuführvorrichtung
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US6589948B1 (en) 2000-11-28 2003-07-08 Eukarion, Inc. Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
US20070269379A1 (en) 2003-07-23 2007-11-22 Samir Mitragotri Penetration Enhancer Combinations for Transdermal Delivery
EP2279177A1 (en) 2008-04-22 2011-02-02 Merck Frosst Canada Ltd. Novel substituted heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US10272035B2 (en) * 2008-11-13 2019-04-30 Gholam A. Peyman Ophthalmic drug delivery method
US20170157038A1 (en) * 2008-11-13 2017-06-08 Gholam A. Peyman Ophthalmic drug delivery method
US8691580B2 (en) 2010-04-09 2014-04-08 Merck Sharp & Dohme Corp. Single chemical entities and methods for delivery of oligonucleotides
EP2588127A4 (en) 2010-06-24 2014-06-11 Univ Indiana Res & Tech Corp DIPEPTIDE-NETWORKED MEDICAL ACTIVE SUBSTANCES
MX2014004953A (es) 2011-11-03 2014-05-28 Bayer Ip Gmbh Ligadores basados en tirosina para la conexion desprendible de peptidos.
US20140357563A1 (en) 2011-12-09 2014-12-04 The Children's Hospital Of Philadelphia Compositions and Methods for the Generation of Activated Protein C and Methods of Use Thereof
EP2916827B1 (en) * 2012-11-08 2020-06-10 Clearside Biomedical Inc. Methods for the treatment of ocular disease in human subjects
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
GB201401453D0 (en) 2014-01-28 2014-03-12 Univ Birmingham Transmucosal and transepithelial drug delivery system
GB201403268D0 (en) 2014-02-25 2014-04-09 Univ Birmingham Antimicrobial surface
CN117180445A (zh) 2014-05-28 2023-12-08 梅德瑞斯糖尿病有限责任公司 针对胰岛素抵抗的改良肽药物
CA3001661C (en) * 2015-10-14 2025-05-06 Massachusetts Eye And Ear Infirmary HIGH-DOSE STATINS FOR AGE-RELATED MACULAR DEGENERATION
CN106668860B (zh) * 2015-11-09 2019-11-22 烟台大学 靶向眼后段的递药系统及其制剂和制备方法
WO2018161035A1 (en) * 2017-03-03 2018-09-07 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents

Similar Documents

Publication Publication Date Title
US10905770B2 (en) Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases
JP2020528082A5 (2)
US20180296525A1 (en) Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents
JP2020514407A (ja) アポリポプロテイン模倣物を用いる加齢黄斑変性と他の眼疾患の治療
US20210138034A1 (en) Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics
US11413322B2 (en) Immunotherapy for angiogenic disease
US10766942B2 (en) Fragments of syndecan-2 having anti-angiogenic activity
TWI581801B (zh) 治療血管新生相關之眼疾之組合物及方法
ES2644016T3 (es) Péptidos para su uso en el tratamiento tópico de enfermedades neurodegenerativas retinianas, en particular en estadios tempranos de retinopatía diabética y otras enfermedades retinianas en las que la neurodegeneración desempeña un papel esencial
EP3238746B1 (en) High-density lipoprotein, and delivery of drug to posterior segment of eye by ocular instillation of said cytophilic peptide-fused high-density lipoprotein
US20160022769A1 (en) Compostions and methods for treating retinal disease
JP6944463B2 (ja) 眼疾患の治療のための組成物及び方法
US20240000891A1 (en) Growth and differentiation factor 15 for treatment of proliferative vitreoretinopathy therapy
JP2020518675A (ja) ノリン誘発性の遺伝子発現および疾患を処置するためのその使用
KR20180102091A (ko) 당뇨병의 치료를 위한 약제학적 제제
HK40011780A (en) Treatment of age-related degeneration and other eye diseases with apolipoprotein mimetics
HK1245149B (en) Wt1 immunotherapy for intraocular angiogenic disease
HK1245149A1 (en) Wt1 immunotherapy for intraocular angiogenic disease